News Archive


  • March 2015

    A vaccine against placental malaria made with ExpreS2ion® Biotechnologies protein expression technology, ExpreS2, is ready to start human tests in Germany and Benin.
    Placental malaria vaccine to start human tests in Germany and Benin

  • February 2015

    ExpreS2ion® Biotechnologies licenses the ExpreS2 system to the Gene Center in Munich, Germany:Scientists at the Gene Center in Munich are using the ExpreS2 protein production system to address expression of antibody fragment and other “challenging to express” proteins, in their research efforts to understand how cells detect damaged DNA and viral RNA.
    Read the PR: The Gene Center at Ludwig-Maximilians-Universit München and ExpreS2ion Biotechnologies enter a licensing agreement for use of the ExpreS2 technology platform

  • January 2015

    ExpreS2ion® Biotechnologies mentioned in Animal Pharm’s Weekly Briefing.
    Joseph Harvey, Editor of Animal Pharm reports on the presentation by Charlotte Dyring at the Informa Veterinary Vaccine Conference in Brussels, in the article with the title: “Danish CRO offers vaccine development services”
    More information: Animal Pharm

  • October 2014

    ExpreS2ion® Biotechnologies is sponsoring the World Vaccine Conference, Brussels, Belgium, October 13th -15th.
    More information: World Vaccine Conferencen

  • October 2014

    ExpreS2ion® Biotechnologie is presenting at the Epic Biotech, the European Partnering and Investment Conference, London, UK, October 2nd.
    More information: Epic Biotech

  • September 2014

    Miptec 2014, Basel, Switzerland, September 23rd-25th, ExpreS2ion® Biotechnologies is sponsoring the session “Current challenges in protein production in academia
    & industry: membrane proteins, protein complexes & biologics”.
    More information: Miptec 2014

  • September 2014

    ExpreS2ion® Biotechnologie Downstream Scientist Lars Poulsen is presenting at the 5th Congress Industrial Cell Technology, Lübeck, Germany, September 11th – 12th.
    More information: 5th Congress Industrial Cell Technology

  • September 2014

    ExpreS2ion® Biotechnologies will participate in the NLSD, Stockholm, Sweden, the largest Life Science Partnering Conference in the Nordic region, September 8th – 9th.
    More information: NLSD

  • September 2014

    Charlotte Dyring, CEO and Co-Founder of ExpreS2ion® Biotechnologiesis participating in a panel discussion at the Global Pharma Manufacturing Summit, Boston, USA, September 8th – 9th.
    More information: Global Pharma Manufacturing Summit

  • August 2014

    ExpreS2ion® Biotechnologies today announces the publication of the article: “Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies” in the high impact scientific journal Nature, with teams at the University of Oxford. Enabled by the ExpreS2 technology platform, the study provides a significant step in understanding the binding of the malaria parasite to blood cells.
    Read the PR here: A significant step in understanding the binding of the malaria parasite to blood cells enabled by the ExpreS2 technology platform

  • August 2014

    “Improving yields in a novel Drosophila S2 Expression System”: Wian de Jongh will present at the 6th Annual Bioprocessing summit in Boston, USA
    Read more: http://www.bioprocessingsummit.com/bpd_content.aspx?id=137120&libID=137091

  • May 2014

    PEGS 2014, Boston, USA. The CSO of ExpreS²ion Wian de Jongh is presenting a poster entitled “Expression of Difficult to Express Proteins using the Drosophila S2-based ExpreS² system”

  • February 2014

    ExpreS2ion Biotechnologies is mentioned in “Ingeniøren”. Follow the link to read the article (in Danish).
    Read more: Ingeniøren

  • October 2013

    ExpreS2ion Biotechnologies is a Nordic Star: selected by the hosts to Nordic Life Sciences Days, which took place in Stockholm, October 14-15.
    Read more: Nordic Star

  • October 2013

    ExpreS2ion Biotechnologies is again sponsoring the 14th Annual World Vaccine Congress, taking place in France, October 16-17.
    Event website: http://www.terrapinn.com/2013/world-vaccine-congress-europe/

  • August 2013

    ExpreS2ion Biotechnologies welcomes Thomas Joergensen, MSc., who will support both up- and downstream development.
    Thomas has successfully concluded his MSc from DTU, working with ExpreS2ion in developing 96-well based screening methods.

  • June 2013

    Presentation at the “World Biopharm Forum 2013: Continuous Processing in Biopharmaceutical Manufacturing”, July 1-2, Cambridge, UK.
    Wian de Jongh, ExpreS2ion Biotechnologies CSO is giving a presentation entitled “Perfusion based production of sub-unit protein vaccines using Drosophila S2 insect cells”.

  • June 2013

    ExpreS2ion Biotechnologies is presenting a poster at the 23rd ESACT meeting “Better Cells for Better Health”, in Lille, France.
    http://esact.org/index.aspx?p=MenuPage&MenuId=119

  • May 2013

    ExpreS2ion Biotechnologies welcomes Max Søgaard PhD, who will develop downstream processing capabilities.
    Max has previously worked at the Division of Structural Biology and the Department of Biochemistry both at University of Oxford in the UK. Here he worked to produce and biophysically characterise a range of proteins for structural studies. He gained his PhD at Cancer Research UK working on the biochemistry of transcription activation in yeast. In collaboration with clients Max will use his extensive experience in protein biochemistry to develop purification strategies for individual targets.

  • 30 April 2013

    ExpreS2ion Biotechnologies is presenting at PEGS 2013. “Development of a Drosophila S2 Insect Cell-Based Malaria Vaccine Production Process”. Presentation on Tuesday, April 30, 10:45, EXPRESSION STREAM Difficult to Express Proteins.
    Event website:http://www.pegsummit.com/PEGS_Content.aspx?id=121426&libID=121374

  • April 2013

    ExpreS2ion Biotechnologies is sponsoring the World Vaccine Congress 16-18 April 2013, Washington DC, USA. This is a great opportunity to catch up on the most recent vaccine trends and developments, and to find out more about how the Drosophila-based ExpreS2 platform can help solve your “protein dead-ends” in vaccine development.
    Event website: http://www.terrapinn.com/2013/world-vaccine-congress-washington/index.stm

  • April 2013

    ExpreS2ion Biotechnologies is hiring :
    Technician job ad Apr 2013

  • March 2013

    ExpreS2ion Biotechnologies is giving a presentation about our proprietary Drosophila S2-based protein expression platform, ExpreS2, at the conference: “New Cells, New Vaccines VII: Protein to Product” , March 17th-20th in Wilmington, DE, USA.
    Find more about the event at: http://www.ncnv.org

  • March 2013

    Wian de Jongh,ExpreS2ion Biotechnologies CSO will present recent protein production results from a placental malaria vaccine project, using the ExpreS2 platform at “6th Annual Cell Culture Technology Event” in March 7th in London.
    Event Web site: http://www.regonline.co.uk/cellculture2013

  • February 2013

    Lars Poulsen PhD joins ExpreS2ion Biotechnologies as Upstream Scientist.
    Lars has completed his PhD at DTU, on a project titled: “Regulatory processes in Aspergillus niger”. The project focused on regulatory mechanisms in the traditional cell factory Aspergillus niger aiming at evaluating the effects on metabolism of gene deletion and/or overexpression studies in putative regulatory genes. During his work Lars has gained profound experience in fungal physiology, metabolism and fermentation as well as a widespread knowledge towards Systems Biology approaches. At ExpreS2ion Biotechnologies, Lars will focus on upstream process development for recombinant protein production with the ExpreS2 Drosophila S2 cells-based platform.

  • November 2012

    ExpreS2ion Biotechnologies is hiring :
    Scientist, Downstream Development
    Scientist, Upstream Development

  • October 2012

    ExpreS2ion Biotechnologies is sponsoring the Session “Strategies to improve production” – Stream C “Vaccine Manufacturing” at the World Vaccine Congress in Lyon, 16-18 October.http://www.terrapinn.com/2012/world-vaccine-congress-lyon/sponsors-list.stm

  • September 2012

    ExpreS2ion Biotechnologies is sponsoring the User Group Meeting “Current Challenges in Protein Expression” at MipTec, 24-25 September in Basel, CH. Miptec is the leading European event for Drug Discovery.
    http://www.miptec.ch/scientific-program/user-group-meetings/current-challenges-in-protein-expression.html

  • July 2012

    Article published in IPI Journal : “A Robust, Scalable Platform for Recombinant Protein Expression” Click on the link to read the article online.
    http://issuu.com/mark123/docs/ipi_volume_4_issue_2/39

  • May 2012

    ExpreS2ion Biotechnologies will be in Cambridge, UK to participate in the Life Sciences Leadership series organized by OneNucleus: “Infectious diseases and Vaccines”, 17 May.

    ExpreS2ion Biotechnologies is participating in the “B4B Connection Oncologie”, Paris, France, 23-24 May

    ExpreS2ion Biotechnologies will be attending the 2nd annual Non-Antibody Protein Production Conference, Prague, Czech Republic, 24-25 May

  • April 2012

    ExpreS2ion Biotechnologies is exhibiting at the World Vaccine Congress in Washington, D.C., April 10-13.

    ISBioTech Meeting, April 2-4: Charlotte Dyring will give a presentation on the opening day

    ExpreS2 technology showcased in BioProcessing Journal

  • February 2012

    New employee at ExpreS2ion Biotechnologies : We are happy to welcome Sancha Salgueiro as the Vice President, Business Development.